Hemoglobinopathies Market Size & Forecast By Type, By Therapy, By Diagnosis And Trend Analysis From 2012 To 2022

Description: Global hemoglobinopathies market is expected to reach over USD 8.82 billion by 2022. Rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering drivers of the market. According to the WHO, hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant variation.

Prevalence of hemoglobinopathies is high in low-income countries such as Sub Saharan region and South East Asia. 85% of the affected population in the U.S. and Europe has ancestral base in these regions.

Governments are collaborating with local institutes to undertake awareness programs for curbing the effect of hemoglobinopathies-related mortality rate. For instance, Thalassemia Data Collection Project and Registry and Surveillance System for Hemoglobinopathies (RuSH) projects were started in 2010 by the Centers for Disease Control and Prevention (CDC).

Low level of hygiene, insufficient healthcare infrastructure, and lesser awareness levels are some key factors attributing to increase in base of target population in low-income regions such as South East Asia, Mediterranean basin, and Africa.

Further key findings from the study suggest:

The market for Sickle Cell Disease (SCD) was the largest with revenue valued at over USD 2,290.0 million in 2014. Rising prevalence of hemoglobinopathies and presence of strong product pipeline for sickle cell anemia such as HQK-1001 and Luspatercept are growth promoting factors of this market.

Genetic testing for diagnosis of sickle cell disorders is expected to witness lucrative growth over the forecast period. It is estimated to grow at a CAGR of around 7.0%. Increasing awareness levels among people coupled with government programs such as the National Sickle Cell Disease Control Program conducted by the WHO in Africa are anticipated to enhance the usage rates for diagnostic tests pertaining to SCD.

Hydroxyurea was one of the dominating segments of the SCD therapy market owing to the presence of the FDA-approved drugs such as Droxia and Hydrea by Bristol Myers Squib. SCD. Thalassemia market holds an extensive product portfolio in pipeline and their expected commercialization is anticipated to drive market growth. For instance, The Ellis Lab is developing a gene therapy for SCD in collaboration with Dr. Victor Garcia.

Blood tests including cell blood count and iron studies are the widely used techniques for diagnosis of thalassemia. On the other hand, pre-implant genetic testing is estimated to grow at lucrative growth rate over 8.5% in the next six years owing to rising base of health conscious population and increasing healthcare expenditure.

The market for blood transfusion was the largest with revenues valued at over USD 1,408.0 million in therapeutic segment owing to, high acceptance level of this treatment option and significant success rate. It is estimated that around 85% of infants below five years suffering from thalassemia die due to insufficient blood transfusion.

North America dominated the overall hemoglobinopathies market in terms of revenue in 2014 at over USD 1,212.0 million. Growing prevalence of blood disorders, favorable government programs, and high level of awareness among healthcare professionals and patients for hemoglobinopathies-related genetic testing are factors attributing to the major share of this market.

Asia Pacific market is expected to witness lucrative growth over the forecast period with a CAGR of over 10% owing to the presence of high unmet clinical needs, improving healthcare infrastructure, and rising economic levels. Moreover, introduction of low-cost diagnostic alternatives will enhance adoption rates for hemoglobinopathies diagnostics market.

Contents: 1 Methodology and Scope 1.1 Research Methodology 1.2 Research Scope & Assumptions 1.3 List of Data Sources
1.4 Known, Unknown variables & target segment

2 Executive Summary

3 Hemoglobinopathies Industry Outlook
3.1 Market segmentation
3.2 Market size and growth prospects
3.3 Hemoglobinopathies: Market dynamics
3.3.1 Market Driver Analysis
3.3.1 Market Restraint Analysis
3.4 Key opportunity analysis, by type- 2014
3.5 Industry analysis Porter’s
3.6 Hemoglobinopathies: PESTEL Analysis
3.7 Hemoglobinopathies Market: Government Regulations
3.7.1 Sickle Cell Disease (SCD) drug development
3.7.2 Drug development for Thalassemia
3.8 Hemoglobinopathies Market: Need Gap Analysis
3.8.1 Prevalence
3.8.2 Treatment efficacy
3.8.3 Therapeutic gap

4 Hemoglobinopathies Therapy Outlook
4.1 Hemoglobinopathies market share by therapy, 2014 & 2022
4.2 Thalassemia therapy
4.2.1 Thalassemia therapy market, 2012 - 2022 (USD Million)
4.2.2 Alpha thalassemia therapy
4.2.2.1 Alpha thalassemia therapy market, 2012 - 2022 (USD Million)
4.2.3 Beta thalassemia therapy
4.2.3.1 Beta thalassemia therapy market, 2012 - 2022 (USD Million)
4.3 Sickle Cell Disease (SCD) therapy
4.3.1 Sickle Cell Disease (SCD) therapy market, 2012 - 2022 (USD Million)
4.4 Other therapy
4.4.1 Other haemoglobin variants therapy market, 2012 - 2022 (USD Million)

5 Hemoglobinopathies Diagnosis Outlook
5.1 Hemoglobinopathies market share by diagnosis, 2014 & 2022
5.2 Thalassemia diagnosis
5.2.1 Thalassemia diagnosis market, 2012 - 2022 (USD Million)
5.2.2 Alpha thalassemia diagnosis
5.2.2.1 Alpha thalassemia diagnosis market, 2012 - 2022 (USD Million)
5.2.3 Beta thalassemia diagnosis
5.2.3.1 Beta thalassemia diagnosis market, 2012 - 2022 (USD Million)
5.3 Sickle Cell Disease (SCD) diagnosis
5.3.1 Sickle Cell Disease (SCD) diagnosis market, 2012 - 2022 (USD Million)
5.4 Other hemoglobin variants
5.4.1 Other haemoglobin variants market, 2012 - 2022 (USD Million)

6 Hemoglobinopathies Regional Outlook
6.1 Hemoglobinopathies market Share by Region, 2014 & 2022
6.2 North America
6.2.2 U.S.
6.2.4 Canada
6.3 Europe
6.3.1 Europe Hemoglobinopathies Market, 2012 - 2022 (USD Million)
6.3.2 UK
6.3.3 UK Hemoglobinopathies Market, 2012 - 2022 (USD Million)
6.3.4 Germany
6.3.5 Germany Hemoglobinopathies Market, 2012 - 2022 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Hemoglobinopathies Market, 2012 - 2022 (USD Million)
6.4.2 Japan
6.4.4 China
6.4.5 China Hemoglobinopathies Market, 2012 - 2022 (USD Million)
6.5 Latin America
6.5.1 Latin America Hemoglobinopathies Market, 2012 - 2022 (USD Million)
6.5.2 Brazil
6.5.3 Brazil Hemoglobinopathies Market, 2012 - 2022 (USD Million)
6.5.4 Mexico
6.5.5 Mexico Hemoglobinopathies Market, 2012 - 2022 (USD Million)
6.6 MEA
6.6.2 South Africa
6.6.3 South Africa Hemoglobinopathies Market, 2012 - 2022 (USD Million)

7 Competitive Landscape
7.1 Gamida Cell
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Alnylam Pharmaceuticals
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Biogen Idec
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Sangamo BioSciences Inc.
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 Genetix Pharmaceuticals/Bluebird Bio
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
7.6 Global Blood Therapeutics Inc.
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.6.4 Strategic Initiatives
7.7 Pfizer Inc.
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Product Benchmarking
7.7.4 Strategic Initiatives
7.8 Mast Therapeutics
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Product Benchmarking
7.8.4 Strategic Initiatives
7.9 Emmaus Life Sciences, Inc.
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Product Benchmarking
7.9.4 Strategic Initiatives
7.10 Prolong Pharmaceuticals
7.10.1 Company Overview
7.10.2 Financial Performance
7.10.3 Product Benchmarking
7.10.4 Strategic Initiatives
7.11 Celgene Corporation
7.11.1 Company Overview
7.11.2 Financial Performance
7.11.3 Product Benchmarking
7.11.4 Strategic Initiatives
7.12 HemaQuest Pharmaceuticals
7.12.1 Company Overview
7.12.2 Financial Performance
7.12.3 Product Benchmarking
7.12.4 Strategic Initiatives

List of Tables

Table 1 Hemoglobinopathies- Industry Snapshot & Key Buying Criteria, 2012 - 2022
Table 2 Hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 3 Hemoglobinopathies market, by region, 2012 - 2022 (USD Million)
Table 4 Global Hemoglobinopathies- Key market driver analysis
Table 5 Normal human haemoglobins
Table 6 Sickle cell disease- Estimates in the U.S.
Table 7 Worldwide annual births with various hemoglobin disorders
Table 8 Product pipeline 28
Table 9 Hemoglobinopathies- Key market restraint analysis
Table 10 Ongoing FDA Orphan Grants for SCD
Table 11 Estimated reach of blood transfusion treatment for Beta-Thalassemia in WHO region
Table 12 Estimated reach of iron chelation treatment for Beta-thalassemia in WHO region
Table 13 North America hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 14 North America thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 15 North America thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 16 North America sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 17 North America sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 18 North America other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 19 North America other Hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 20 U.S. Hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 21 U.S. thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 22 U.S. thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 23 U.S. sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 24 U.S. sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 25 U.S. other Hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 26 U.S. other Hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 27 Canada Hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 28 Canada thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 29 Canada thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 30 Canada sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 31 Canada sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 32 Canada other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 33 Canada other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 34 Europe Hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 35 Europe thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 36 Europe thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 37 Europe sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 38 Europe sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 39 Europe other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 40 Europe other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 41 UK Hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 42 UK thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 43 UK thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 44 UK sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 45 UK sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 46 UK other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 47 UK. other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 48 Germany hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 49 Germany thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 50 Germany thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 51 Germany sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 52 Germany sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 53 Germany other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 54 Germany other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 55 Asia Pacific hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 56 Asia Pacific thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 57 Asia Pacific thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 58 Asia Pacific sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 59 Asia Pacific sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 60 Asia Pacific other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 61 Asia Pacific other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 62 Japan hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 63 Japan thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 64 Japan thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 65 Japan sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 66 Japan sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 67 Japan other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 68 Japan other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 69 China hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 70 China thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 71 China thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 72 China sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 73 China sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 74 China other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 75 China other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 76 Latin America hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 77 Latin America thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 78 Latin America thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 79 Latin America sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 80 Latin America sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 81 Latin America other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 82 Latin America other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 83 Brazil hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 84 Brazil thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 85 Brazil thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 86 Brazil sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 87 Brazil sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 88 Brazil other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 89 Brazil other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 90 Mexico hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 91 Mexico thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 92 Mexico thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 93 Mexico sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 94 Mexico sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 95 Mexico other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 96 Mexico other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 97 MEA hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 98 MEA thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 99 MEA thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 100 MEA sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 101 MEA sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 102 MEA other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 103 MEA other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)
Table 105 South Africa hemoglobinopathies market, by type, 2012 - 2022 (USD Million)
Table 106 South Africa thalassemia market, by therapy, 2012 - 2022 (USD Million)
Table 107 South Africa thalassemia market, by diagnosis, 2012 - 2022 (USD Million)
Table 108 South Africa sickle cell disease market, by therapy, 2012 - 2022 (USD Million)
Table 109 South Africa sickle cell disease market, by diagnosis, 2012 - 2022 (USD Million)
Table 110 South Africa other hemoglobin variants market, by therapy, 2012 - 2022 (USD Million)
Table 111 South Africa other hemoglobin variants market, by diagnosis, 2012 - 2022 (USD Million)

List of Figures

Figure 1 Hemoglobinopathies : Market segmentation
Figure 2 Hemoglobinopathies market, 2012 - 2022 (USD Million)
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | Hemoglobinopathies Market Size & Forecast By Type, By Therapy, By Diagnosis And Trend Analysis From 2012 To 2022 |
| Web Address:  | http://www.researchandmarkets.com/reports/3640132/              |
| Office Code:  | SCBR9VO1                                                          |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
<td>USD 4700</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
<td>USD 8000</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
<td>USD 10500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐  Mrs ☐  Dr ☐  Miss ☐  Ms ☐  Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World